B-Type Natriuretic Peptides and Echocardiographic Measures of Cardiac Structure and Function

JACC: Cardiovascular Imaging

Volumn 2, Issue 2, 2009, Pages 216-225

  Troughton, Richard W ^a   Richards, A Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Doppler echocardiography; echocardiography; left ventricular function; natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

CARDIOVASCULAR DISEASE; COMMUNITY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; HEALTH STATUS; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MEDICAL DECISION MAKING; MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING; VALVULAR HEART DISEASE;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; HEART FAILURE; HEART VALVE DISEASES; HUMANS; MYOCARDIAL CONTRACTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 59649110510     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2008.12.006     Document Type: Review

References (71)

1. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 (1991) 1402-1412
2. Hunt P.J., Yandle T.G., Nicholls M.G., Richards A.M., and Espiner E.A. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 214 (1995) 1175-1183
3. Daniels L.B., and Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 50 (2007) 2357-2368
4. Martinez-Rumayor A., Richards A.M., Burnett J.C., and Januzzi Jr. J.L. Biology of the natriuretic peptides. Am J Cardiol 101 (2008) 3-8
5. Lam C.S., Burnett Jr. J.C., Costello-Boerrigter L., Rodeheffer R.J., and Redfield M.M. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 49 (2007) 1193-1202
6. Tang W.H., Francis G.S., Morrow D.A., et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 116 (2007) e99-e109
7. Hammerer-Lercher A., Ludwig W., Falkensammer G., et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 50 (2004) 1174-1183
8. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
9. Das S.R., Drazner M.H., Dries D.L., et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112 (2005) 2163-2168
10. Vickery S., Price C.P., John R.I., et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 46 (2005) 610-620
11. Ordonez-Llanos J., Collinson P.O., and Christenson R.H. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 101 (2008) 9-15
12. Groenning B.A., Raymond I., Hildebrandt P.R., Nilsson J.C., Baumann M., and Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90 (2004) 297-303
13. Costello-Boerrigter L.C., Boerrigter G., Redfield M.M., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47 (2006) 345-353
14. Yamamoto K., Burnett Jr. J.C., Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 (1996) 988-994
15. Iwanaga Y., Nishi I., Furuichi S., et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47 (2006) 742-748
16. Yamaguchi H., Yoshida J., Yamamoto K., et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 43 (2004) 55-60
17. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105 (2002) 595-601
18. Troughton R.W., Prior D.L., Pereira J.J., et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43 (2004) 416-422
19. Tschope C., Kasner M., Westermann D., Gaub R., Poller W.C., and Schultheiss H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26 (2005) 2277-2284
20. Abhayaratna W.P., Marwick T.H., Becker N.G., Jeffery I.M., McGill D.A., and Smith W.T. Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. Am Heart J 152 (2006) 941-948
21. Lim T.K., Ashrafian H., Dwivedi G., Collinson P.O., and Senior R. Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: implication for diagnosis of diastolic heart failure. Eur J Heart Fail 8 (2006) 38-45
22. Mariano-Goulart D., Eberle M.C., Boudousq V., et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail 5 (2003) 481-488
23. Bansal M., and Marwick T.H. Natriuretic peptides and filling pressure at rest and stress. Heart Fail Clin 4 (2008) 71-86
24. Omland T., Aakvaag A., and Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 76 (1996) 232-237
25. Parsonage W.A., Galbraith A.J., Koerbin G.L., and Potter J.M. Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 95 (2005) 883-885
26. Maeda K., Tsutamoto T., Wada A., Hisanaga T., and Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 (1998) 825-832
27. Dokainish H., Zoghbi W.A., Lakkis N.M., et al. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 109 (2004) 2432-2439
28. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7 (2001) 21-29
29. Braunschweig F., Fahrleitner-Pammer A., Mangiavacchi M., et al. Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. Eur J Heart Fail 8 (2006) 797-803
30. Nagueh S.F., Middleton K.J., Kopelen H.A., Zoghbi W.A., and Quinones M.A. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30 (1997) 1527-1533
31. Ommen S.R., Nishimura R.A., Appleton C.P., et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 102 (2000) 1788-1794
32. Lester S.J., Tajik A.J., Nishimura R.A., Oh J.K., Khandheria B.K., and Seward J.B. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. J Am Coll Cardiol 51 (2008) 679-689
33. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109 (2004) 3176-3181
34. Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., and Whooley M.A. Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease?. Data from the Heart and Soul Study. Am J Med 116 (2004) 509-516
35. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA 288 (2002) 1252-1259
36. Maisel A.S., Koon J., Krishnaswamy P., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 141 (2001) 367-374
37. McDonagh T.A., Morrison C.E., Lawrence A., et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 350 (1997) 829-833
38. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham Heart Study. JAMA 288 (2002) 1252-1259
39. McDonagh T.A., Cunningham A.D., Morrison C.E., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86 (2001) 21-26
40. Lim T.K., Dwivedi G., Hayat S., Collinson P.O., and Senior R. Cost effectiveness of the B type natriuretic peptide, electrocardiography, and portable echocardiography for the assessment of patients from the community with suspected heart failure. Echocardiography 24 (2007) 228-236
41. Marwick T.H., and Schwaiger M. The future of cardiovascular imaging in the diagnosis and management of heart failure, part 2: clinical applications. Circ Cardiovasc Imaging 1 (2008) 162-170
42. Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., and Whooley M.A. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 108 (2003) 2987-2992
43. Ng L.L., Loke I., Davies J.E., et al. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail 5 (2003) 775-782
44. Heidenreich P.A., Gubens M.A., Fonarow G.C., Konstam M.A., Stevenson L.W., and Shekelle P.G. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43 (2004) 1019-1026
45. Corteville D.C., Bibbins-Domingo K., Wu A.H., Ali S., Schiller N.B., and Whooley M.A. N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the Heart and Soul Study. Arch Intern Med 167 (2007) 483-489
46. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
47. Wright S.P., Doughty R.N., Pearl A., et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 42 (2003) 1793-1800
48. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006) 330-337
49. Maisel A.S., McCord J., Nowak R.M., et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41 (2003) 2010-2017
50. Dokainish H., Zoghbi W.A., Lakkis N.M., Quinones M.A., and Nagueh S.F. Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. Am J Cardiol 93 (2004) 1130-1135
51. Huang C.H., Tsai M.S., Hsieh C.C., Wang T.D., Chang W.T., and Chen W.J. Diagnostic accuracy of tissue Doppler echocardiography for patients with acute heart failure. Heart 92 (2006) 1790-1794
52. Logeart D., Saudubray C., Beyne P., et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 40 (2002) 1794-1800
53. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
54. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 (2007) 1733-1739
55. Coletta A.P., Cullington D., Clark A.L., and Cleland J.G.F. Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF. Eur J Heart Fail 10 (2008) 1264-1267
56. Gackowski A., Isnard R., Golmard J.L., et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 25 (2004) 1788-1796
57. Wasywich C.A., Whalley G.A., Walsh H.A., Gamble G.D., and Doughty R.N. The relationship between BNP and E/Ea in patients hospitalized with acute heart failure. Int J Cardiol 125 (2008) 280-282
58. Gruppo Italiano per lo Studio della Sopravvivenza, Nell'infarto M., Nicolosi G.L., Latini R., et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Eur Heart J 17 (1996) 1646-1656
59. Yu C.M., Sanderson J.E., Marwick T.H., and Oh J.K. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol 49 (2007) 1903-1914
60. Moller J.E., Whalley G.A., Dini F.L., et al. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. Circulation 117 (2008) 2591-2598
61. Olsen M.H., Hansen T.W., Christensen M.K., et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28 (2007) 1374-1381
62. Dokainish H., Zoghbi W.A., Lakkis N.M., et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol 45 (2005) 1223-1226
63. Whalley G.A., Wright S.P., Pearl A., et al. Prognostic role of echocardiography and brain natriuretic peptide in symptomatic breathless patients in the community. Eur Heart J 29 (2008) 509-516
64. Richards A.M., Nicholls M.G., Espiner E.A., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
65. Olsen M.H., Wachtell K., Tuxen C., et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 22 (2004) 1597-1604
66. Bergler-Klein J., Mundigler G., Pibarot P., et al. B-type natriuretic peptide in low-flow, low-gradient aortic stenosis: relationship to hemodynamics and clinical outcome: results from the Multicenter Truly or Pseudo-Severe Aortic Stenosis (TOPAS) study. Circulation 115 (2007) 2848-2855
67. Gerber I.L., Stewart R.A., Legget M.E., et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107 (2003) 1884-1890
68. Weber M., Hausen M., Arnold R., et al. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 92 (2006) 1639-1644
69. Gerber I.L., Stewart R.A., French J.K., et al. Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol 92 (2003) 755-758
70. Sutton T.M., Stewart R.A., Gerber I.L., et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 (2003) 2280-2287
71. Weber M., Hausen M., Arnold R., et al. Diagnostic and prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients with chronic aortic regurgitation. Int J Cardiol 127 (2008) 321-327